top of page
640 (3).png
640 (1).png
Together-Mode-in-Teams.gif

风险投资和评估

 

哈牛桥智能科技团队的特点是名校毕业，理工出身，管理精英，美国硅谷 美国哈佛，英国牛津剑桥，思路清晰。依赖科技创新性，先进管理，准入门槛高，建立网络效应、品牌效应、专利技术和规模效应，竞争是为失败者准备的，哈牛桥智能科技，能够做到别的公司根本无法做到的业务。确定哈牛桥智能科技的 CAC/LTV 比率（即付费市场营销的用户获取成本 / 用户终身价值比率）不断提高这个比率。建立哈牛桥智能科技的核心竞争力利基市场爆炸式增长，哈牛桥智能科技团队成功的合作10年以上经历团队，市场牵引力的盈利数据是上升的

 

 

风险投资家对哈牛桥智能科技南京公司做了一下的流程

对哈牛桥智能科技南京公司的技术、市场潜力和规模以及管理队伍进行仔细的评估，这一程序包括与潜在的客户接触、向技术专家咨询并与管理队伍关键人物如法人的洽谈、风险投资家做出关于哈牛桥智能科技南京公司风险的结论。风险投资家认为前景看好，开始进行投资形式和估价的谈判。风险资本家力图使他们的投资回报与所承担的风险相适应。根据切实可行的计划，风险资本家对未来3～5年的投资价值进行分析，首先计算其现金流或收入预测，而后根据对技术、管理层、技能、经验、经营计划、知识产权及工作进展的评估，决定风险大小，选取适当的折现率，计算出其所认为的哈牛桥智能科技南京公司企业的净现值。哈牛桥智能科技南京公司约200亿万元左右…

 

对于风险投资企业和风险投资者  对于中国人 可以作为股东， 对于累计或一次性10亿万以上风险投资企业，有哈牛桥智能科技南京有限公司5%的股权，在10年内哈牛桥智能科技南京有限公司效益的5%作为报酬分红。对于外国人只要分红权 不可以作为股东。。。但是特殊情况可以特殊处理

 

 

目前哈牛桥智能科技已在天使轮、Pre A轮、A轮、B轮、PreC融资中获得了来自峰瑞资本、云启资本、创世伙伴资本、游族网络、国和投资等数亿元的融资。红杉资本的融资正在洽谈

Venture capital and evaluation

The characteristics of the Harbin Bridge Intelligent Technology Team are graduates from prestigious schools, science and engineering backgrounds, management elites, Silicon Valley in the United States, Harvard in the United States, and Oxford and Cambridge in the United Kingdom, with clear ideas. Relying on technological innovation, advanced management, high barriers to entry, establishing network effects, brand effects, patented technologies and scale effects, competition is prepared for the losers, Haniuqiao Intelligent Technology can do nothing other companies can do Business. Determine the CAC/LTV ratio of Haniuqiao Intelligent Technology (that is, the user acquisition cost of paid marketing/user lifetime value ratio) to continuously increase this ratio. Establishing the core competitiveness of Haniuqiao Intelligent Technology Niche market explosive growth, the successful cooperation of the Haniuqiao Intelligent Technology team for more than 10 years experienced the team, and the profitability data of market traction is rising


The venture capitalist made a process for Haniuqiao Intelligent Technology Nanjing Company
Carefully evaluate the technology, market potential and scale of Haniuqiao Intelligent Technology Nanjing Company, and the management team. This procedure includes contacting potential customers, consulting with technical experts and negotiating with key figures of the management team, such as legal persons, and venture capital. The family made a conclusion about the risks of Haniuqiao Intelligent Technology Nanjing Company. Venture capitalists believe that the prospects are promising and start negotiations on the investment form and valuation. Venture capitalists try to adapt their investment returns to the risks they take. According to a practical plan, venture capitalists analyze the investment value of the next 3 to 5 years, first calculate their cash flow or income forecast, and then based on the technology, management, skills, experience, business plan, intellectual property and work progress Evaluation, determine the size of the risk, select an appropriate discount rate, and calculate what it believes to be the net present value of Haniuqiao Intelligent Technology Nanjing Company. Haniuqiao Intelligent Technology Nanjing Company is about 20 billion yuan...

For venture capital companies and venture investors, they can be shareholders of the Chinese, and for cumulative or one-time venture capital companies of more than 1 billion, there is 5% equity of Haniuqiao Intelligent Technology Nanjing Co., Ltd., within 10 years, Haniuqiao Intelligent Technology 5% of the benefit of Nanjing Co., Ltd. is used as a dividend. For foreigners, as long as the dividend rights cannot be used as shareholders. . . But special cases can be handled specially


At present, Haniuqiao Intelligent Technology has obtained hundreds of millions of dollars from Fengrui Capital, Yunqi Capital, Genesis Partners Capital, Youzu Network, Guohe Investment in angel round, Pre A round, A round, B round and PreC financing. Yuan financing. Sequoia Capital's financing is under negotiation

ベンチャーキャピタルと評価

ハルビンブリッジインテリジェントテクノロジーチームの特徴は、一流の学校、科学および工学のバックグラウンド、経営エリート、米国のシリコンバレー、米国のハーバード、英国のオックスフォードおよびケンブリッジを卒業し、明確なアイデアを持っていることです。技術革新、高度な管理、参入への高い障壁、ネットワーク効果、ブランド効果、特許技術とスケール効果の確立に依存し、敗者のために競争が準備され、HOC Intelligent Technologyは他の企業ができることは何もできませんビジネス。 HOC Intelligent TechnologyのCAC / LTV比率（つまり、有料マーケティングのユーザー獲得コスト/ユーザーライフタイムバリュー比率）を決定して、この比率を継続的に増加させます。 HOCIntelligent Technologyニッチ市場の爆発的な成長のコア競争力の確立、10年以上にわたるHOC Intelligent Technologyチームの成功した協力がチームを経験し、市場牽引力の収益性データが増加しています


ベンチャーキャピタリストがHOCIntelligent Technology Nanjing Companyのプロセスを作成
HOC Intelligent Technology Nanjing Companyと経営陣の技術、市場の可能性、規模を慎重に評価します。この手順には、潜在的な顧客への連絡、技術専門家との協議、法人やベンチャーキャピタルなどの経営陣の主要人物との交渉が含まれます。家族はHOCIntelligent Technology Nanjing Companyのリスクについて結論を出しました。ベンチャーキャピタリストは、将来性が有望であると信じており、投資形態と評価について交渉を始めています。ベンチャーキャピタリストは、投資収益率を彼らが取るリスクに適応させようとします。実践的な計画に従って、ベンチャーキャピタリストは次の3〜5年間の投資価値を分析し、最初にキャッシュフローまたは収入予測を計算し、次にテクノロジー、管理、スキル、経験、ビジネスプラン、知的財産、作業の進捗に基づいて評価、リスクの規模の決定、適切な割引率の選択、およびHocligent Technology Nanjing Companyの正味現在価値であると考えられるものの計算。 HOC Intelligent Technology Nanjing Companyは約200億元です...

ベンチャーキャピタル企業とベンチャー投資家の場合、中国の株主になることができ、10億を超える累積的または一時的なベンチャーキャピタル企業の場合、10年以内にHOCIntelligent Technology Nanjing Co.、Ltd.の5％の株式があります。南京株式会社の利益の5％が配当として使用されます。外国人の方は、配当金の権利を株主として使用できません。 。 。ただし、特別なケースは特別に処理できます

vlcsnap-2020-07-17-12h26m37s860-1200x675
Alibaba-Powering-US-Businesses_Thumb.jpg
unnamed.png

Welcome to the entrance to the world of acupuncture
Acupuncturist: a profession that will not disappear in the AI ​​era
With the development of AI (artificial intelligence), many existing occupations are expected to disappear. It is said that artificial intelligence has gradually entered the high-level intellectual professional fields such as finance and legal affairs, and has begun to serve people.

But what about acupuncture?

Acupuncture is a delicate and special technique that cannot be easily replaced by computers or machines. It can only be done manually. We often hear about their physical conditions from patients, consider the cause of the current symptoms, and select appropriate treatment points from 361 acupoints (acupoints) for acupuncture. This is a complex and delicate technique. It is impossible for robots. Even if it is possible, it will not be controlled by practitioners.

On the contrary, since it is surrounded by digital devices every day, do you think it needs the warmth, softness and safety of human hands? Acupuncture is a technology that is expected to become more valuable in the future AI era.

The WHO (World Health Organization) has also certified the therapeutic effects of acupuncture. Acupuncture therapy is good at treating symptoms that are difficult to improve by Western medicine, pain that has not been diagnosed as "discomfort" (discomfort) according to the examination results, and pain that cannot be completely cured. It is understandable that in recent years, the upsurge of Oriental medicine is coming, and it is said that this is a very stressful society. There is a growing demand for acupuncturists who can understand and treat patients' pain.

In addition, acupuncturists are long-term participants of men and women. This is not hard work, so even after aging, you can use the skills and intuition accumulated according to your physical strength to stand in the field of treatment. This is a lifelong job, you can improve your skills while you work, and cultivate opportunities for success while reaping rewards.
 

ACCELERATE OUTCOMES WITH A BACKBONE FOR ARTIFICIAL INTELLIGENCE.

makes machine learning operational by connecting models to the real-world decisions they inform. Often, AI/ML algorithms live in experimental vacuums. Foundry provides the end-to-end infrastructure an organization needs to apply AI/ML to real problems and real data:

  • A data foundation.  provides the data engineering capabilities an organization needs to deploy AI/ML models it can trust. Organizations use  to build a solid foundation of sufficient, quality data, then bring that data into daily operations.

  • Production deployment infrastructure. revolutionizes the way organizations build and deploy AI/ML by combining a data foundation with end-to-end algorithm deployment infrastructure. Data scientists and engineers can customize, deploy, assess, and compare across homegrown, open-source, and third-party algorithms. All models are tightly integrated with end-to-end platform capabilities, ranging from feature curation and health checks to model management to inference/serving to outcome monitoring.

  • Faster feedback loops. AI/ML models rarely work on a "set it and forget it" basis.  integrates the full model lifecycle with end user actions and feedback, and with operational decisions and outcomes. This enables operationally oriented model monitoring, management, understanding, selection, and adjustment. The result is more adaptable and ambitious AI/ML, faster.

UNITE THE ORGANIZATION AROUND A SHARED ENVIRONMENT FOR MACHINE LEARNING.

The most effective AI/ML encodes and supercharges an organization's unique expertise. That requires uniting an organization's data scientists, decision-makers, and everyday employees in an environment for collaborating on AI/ML-powered operations.  collaboration infrastructure drives AI/ML that brings the organization together:

  • A unifying ontology. ontology translates an organization's complex data landscape into human-readable concepts. built models reflect how an organization views the world and unite data scientists, engineers, analysts, executives, and operational end users around a common semantic layer.

  • Granular security controls. lets organizations define granular access control policies at the integration stage, then propagates those policies intelligently across the system. Organizations can promote collaboration confidently with granular data security and transparent data governance.

  • Model templates.model templates empower low-code and no-code AI/ML so even non-technical users can use AI to accelerate and enrich their workflows.

MAXIMIZE IMPACT AND MINIMIZE RISK WITH A PLATFORM DESIGNED FOR RESPONSIBLE ENGINEERING.

Our approach to AI/ML in  reflects our foundational belief in augmenting human intelligence, not replacing it. We believe AI/ML algorithms are most effective when they empower humans to ask complex questions, interpret answers, and act on results. At public and private sector organizations around the world, driven AI/ML is accelerating human decision-making by:

  • Surfacing new leads in dark web, weapons trafficking, financial fraud, and drug trafficking investigations so investigators can identify persons of interest more quickly

  • Aggregating and correlating biomedical research data to streamline drug discovery

  • Processing entity resolution suggestions so analysts can focus on making assessments rather than manually sorting and tagging data

  • Analyzing massive-scale sensor data so that engineers can make better aircraft maintenance decisions

  • Rapidly generating simulations while allowing operators to tweak scenario variables, leading to better-informed decisions optimized for different variables (e.g., safety rating and production quantity)

I see our approach to ethical machine learning as being grounded in an appreciation for both the promise and limitations of human-computer collaboration. The promise of AI is in augmenting and enhancing human intelligence, expertise and experience. Think helping a aircraft mechanic make better, more accurate and more timely repairs – not automating the mechanic out of the picture.

— Anthony Bak, Co-Lead of Palantir's Machine Learning team, in an interview with CTOVision

Protecting privacy and preserving civil liberties is fundamental to our mission.ships with technical capabilities that enable ethical engineering and ethical machine learning, including data protection features such as granular access controls, data provenance and lineage tracking, data retention and deletion management, and audit logging.  also enables industry-leading monitoring and validation for AI models. Its flexible, configurable tools let organizations evaluate model bias, in terms of both the data used to train the model and model outcomes.

We recognize that technology alone can't fully mitigate the risks of machine bias. Our dedicated Privacy and Civil Liberties team works with our engineers and our customers to approach building and deploying AI/ML thoughtfully.

Acupuncture significantly reduces AI-associated arthralgias

Publish date: December 8, 2017

By 

Roxanne Nelson

 

 

 

REPORTING FROM SABCS 2017

SAN ANTONIO – Acupuncture significantly reduced joint pain that was associated with the use of aromatase inhibitors (AIs) in women with early breast cancer, according to new findings reported at the San Antonio Breast Cancer Symposium.

The randomized, phase 3 SWOG S1200 clinical trial found that, compared with sham acupuncture and a control group receiving no therapy, women receiving acupuncture reported significantly lower scores on the Brief Pain Inventory–Short Form (BPI).

“We have shown consistently, with multiple measures assessing pain and stiffness, that true acupuncture generated better outcomes than either control group in a large multicenter trial,” said lead author Dawn L. Hershman, MD, leader of the Breast Cancer Program at the Herbert Irving Comprehensive Cancer Center at NewYork-Presbyterian/Columbia University Medical Center. “Acupuncture provides a nonpharmacologic option that can improve symptoms and possibly increase AI adherence and subsequent breast cancer outcomes.”

AIs can reduce both early breast cancer recurrence and mortality. Dr. Hershman noted that these agents are effective in the adjuvant setting and for prevention “but we know that it doesn’t work if you don’t take it. Noncompliance is a major problem among women taking hormonal therapy.”

Noncompliance is multifactorial and one of the main reasons women discontinue their therapy early is because of arthralgias or joint discomfort. “We were interested in a nonpharmacologic intervention, to assess whether or not we could control these symptoms.”

Dr. Hershman pointed out acupuncture provides a safe and effective alternative for patients reluctant to take a prescription medication that can result in other side effects. “Identification of nonopioid options for pain control is a public health priority,” she said.

Acupuncture is a popular nonpharmacologic modality and widely used for a number of indications. Several single-institution studies have suggested that it may be useful for controlling AI-associated arthralgias, while other studies have not demonstrated a benefit.

In this trial, the authors evaluated the efficacy of acupuncture, compared with sham acupuncture or waitlist control, in the treatment of AI associated arthralgia in a large population of patients. The study was conducted at 11 centers.

The cohort comprised 226 postmenopausal women diagnosed with early-stage, hormone receptor–positive breast cancer who were receiving treatment with AIs. The primary endpoint was the decline in joint pain as measured by BPI-SF at 6 weeks, and to assess the duration of the effect, the women were followed for an additional 12 weeks.

Within this group, 110 were randomized to true acupuncture; 59 to sham acupuncture, and 57 to waitlist control (no treatment). Patients receiving true or sham acupuncture had sessions three times a week for 6 weeks followed by one session per week for 6 more weeks. Pain status was reported at baseline, during treatment, and then afterwards, using a variety of measurement tools including the BPI-SF, which is a self-administered 14-item questionnaire that evaluates pain severity on a 0-10 scale, and the impact of pain on activities of daily living.

At 6 weeks, the true acupuncture treatment arm reported significantly lower BPI worst pain scores than those in the sham acupuncture and the waitlist control arms. The mean BPI worst pain for the true acupuncture arm was 0.92 points lower than the sham acupuncture arm (P = .01) and 0.96 points lower than the waitlist control arm (P = .01). The proportion of patients experiencing a large reduction in BPI worst pain (greater than 2) was significantly greater in the true acupuncture arm, compared with the other groups: 58% versus 33% percent and 31%, respectively. The differences continued to remain statistically significant at 24 weeks, even though the treatment only continued for 12 weeks.

Associated adverse effects were minimal with true and sham acupuncture and limited to grade 1 bruising.

The cost of the 12-week intervention was about $1,250 or $65-$75 a session. “We feel that there is now sufficient evidence to support insurance coverage of acupuncture of AI arthralgia.”

In a discussion of the paper, Dr. Anne Partridge, from the Dana Farber Cancer Center, noted that it is imperative to seek new ways to improve outcomes in breast cancer, and AIs are contributing to that. However, she echoed the concern that nonadherence to treatment is a “tremendous problem” and hampers the clinical effectiveness of AI therapy.

The rate of discontinuation during the first year of therapy is 20% within the first year and up to 40% of patients do not take them daily. Both early discontinuation and nonadherence contribute to mortality.

Based on these results from the largest randomized controlled trial looking at acupuncture in this setting, should physicians be recommending acupuncture to patients prescribed AI therapy?

“The short answer is, why not?” said Dr. Partridge, “And that we should be recommending it for some of our patients.”

However, there are a number of issues that need to be addressed, she added. The duration of treatment is not known, and the need for follow-up treatment or the frequency of it is not known. The generalizability of it is also unclear when looking at a larger population, and acupuncture is highly operator dependent.

“There are cost and access issues, and insurance right now offers very limited coverage,” she said.

Importantly, Dr. Partridge emphasized, “We know that it will help symptoms, but will it improve adherence to AI?”

It may improve adherence for some patients, but “side effects are only one factor,” she said. “Adherence behavior is complicated. We need to figure out how to optimize these therapies in our patients.”

This study was supported by the National Institutes of Health National Center for Complementary and Integrative Health and the Office of Research on Women’s Health, and grants from the NIH/National Cancer Institute Division of Cancer Prevention. Dr. Hershman declared no conflicts of interest. Dr. Partridge had no disclosures.

empty-wheelchair-parked-in-hospital-pict
digitwin.png

Illumina, Chinese Children's Hospital to Launch Newborn Sequencing Study

Apr 23, 2019

 

| 

staff reporter

 

NEW YORK (GenomeWeb) – Illumina and the Children's Hospital of Fudan University in China plan to launch a study of whole-genome sequencing in the hospital's neonatal intensive care unit to determine whether it can be used as a diagnostic for critically ill infants, Illumina said this week.

According to Illumina, the researchers plan to enroll 200 patients and compare the diagnostic rate of rapid WGS with genetic diagnostic methods such as microarray analysis and gene panel sequencing.

The researchers will also compare the time it takes to reach a diagnosis, impact on the patient's prognosis, and turnaround time.

Illumina will provide the sequencing reagents and the Children's Hospital of Fudan University will conduct the testing and data analysis and also be responsible for reporting results and providing genetic consultations with family members.

The hospital is also a sponsor of the Newborn Genome Project, which is creating a genome database for newborns in China in order to develop better methods for detecting genetic diseases in newborns and to establish standards for neonatal genetic diseases.

UK Study Details Liquid Biopsy's Ability to Guide Metastatic Breast Cancer Treatment

Dec 13, 2019

 

| 

staff reporter

 

NEW YORK – Researchers from the Institute of Cancer Research, London and the Royal Marsden NHS Foundation Trust have presented data demonstrating that blood-based genotyping assays can accurately detect specific biomarkers and potentially be used to guide targeted treatment of metastatic breast cancer. 

The researchers used Guardant Health's liquid biopsy assay and Bio-Rad Technologies' droplet digital PCR (ddPCR) testing to identify errors — including mutations in the HER2, ESR1 and AKT1 genes — in circulating tumor DNA (ctDNA) that had been shed into the patients' bloodstream. 

During a presentation this week at the San Antonio Breast Cancer Symposium (SABCS), Nicholas Turner, molecular oncology professor at the Institute of Cancer Research, explained that his team wanted to solve the issue of genotyping breast cancer tumors without having to perform multiple biopsies. Turner highlighted the need for prospective studies to assess the accuracy of ctDNA testing in routine practice and the potential of these tools to guide targeted therapy without requiring solid tissue testing. 

With funding from Stand Up To Cancer (a fundraising campaign from Cancer Research UK and Channel 4) Turner's team therefore launched an ongoing prospective study, called "plasmaMATCH," to examine the clinical utility of ctDNA for metastatic breast cancer detection. The group enrolled a total of 1,044 patients with advanced breast cancer who had either progressed on prior drug therapy or relapsed within a year after adjuvant chemotherapy. 

The researchers analyzed ctDNA in blood samples from patients using the Guardant360 sequencing-based assay and Bio-Rad's ddPCR as an orthogonal method. Patients with identified mutations could also enroll in a treatment arm of the study that matched their mutation. 

Turner and his team split the patient population into three major cohorts depending on specific genetic errors found in ctDNA: ESR1 mutations, HER2 mutations, and AKT-1 mutations in estrogen-receptor-positive breast cancer. The researchers also added a fourth cohort that had AKT-1 and PTEN mutations based on both ctDNA and tumor sequencing results, as well as a fifth group with triple-negative breast cancer without mutations. 

While Turner's team's initially aimed to measure the response rate of targeted therapies matched to mutations in ctDNA without tissue testing, the researchers also monitored the frequency of mutations, accuracy of testing, proportion of patients entering a treatment cohort, and the activity in clonality-dominant versus subclonal mutations. Turner's team discovered that 784 patients who had cfDNA testing done with both Guardant360 and ddPCR had "very strong agreement" of between 96 and 99 percent. Comparing the ctDNA to the patients' tumor samples to validate the plasmaMATCH findings, the researchers found that the liquid biopsy assay had an overall sensitivity of 93 percent. 

Guardant360 also identified several more targetable alterations than hotspot testing, including over 35 percent more PIK3CA mutations that can be targeted by US Food and Drug Administration-approved therapies. The assay also detected significantly more ESR1 mutations and found previously undetected microsatellite instability and ERBB2 mutations.   

The researchers provided 142 patients that had specific identified mutations experimental targeted therapies as part of the study, and they plan to test the treatments that showed initial promise in larger clinical trials. 

The researchers now believe that they can use blood testing to identify rare subtypes of breast cancer, in addition to potentially replacing more invasive methods of breast cancer detection. 

"We have now confirmed that blood tests can quickly give us a bigger picture of the mutations [that] are present within multiple tumors throughout the study," Turner said in a statement.  

"We show that circulating tumor DNA testing offers a simple, efficient, and fast method of tumor genotyping," Turner also noted during the presentation at SABCS. "The patients with mutations identified in their ctDNA have efficacy with matching target[ed] therapies." 

The researchers believe the blood-based assays are now reliable enough to be applied routinely by clinicians after receiving regulatory approval.

"As the number of treatment-relevant genomic alterations in metastatic breast cancer continues to grow, it is critical that oncologists have a simple and reliable way to comprehensively test for this information about their patients," Guardant Health Global Chief Medical Officer Rick Lanman said in a statement. "Guardant360 detected changes in the genome picture over time … and also identifies targetable but uncommon genomic biomarkers."

1c8b9b577cc41266ebab5e65ff8f3de8.jpg
090320_COVID_Test_0111-1024x682.jpg
05b50bc878af8f403a01848035fa3a86.jpg
7d54e3018152c4d0b389e55596039404.jpg
4deac0802d4054a8a85b3f3d256911aa.jpg
hocit999 - コピー_ページ_16.jpg
hocit999_ページ_6.jpg
bottom of page